Physician profile
Peter Winters
NPI 1326042060
$993.74
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $140 · 2021: $45.38 · 2022: $99.99 · 2023: $14.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.42 | 2019 | |
| Janssen Biotech, INC. | $168.72 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $127.46 | 2019-2021 | |
| Lilly USA, LLC | $90.31 | 2019-2021 | |
| Pfizer INC. | $71.45 | 2019-2020 | |
| Amgen INC. | $53.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.57 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.28 | 2019 | |
| Mayne Pharma Commercial LLC | $29.60 | 2019 | |
| Epi Health, LLC | $23.54 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.01 | 2019 | |
| Galderma Laboratories, L.P. | $18.35 | 2020 | |
| Dermira, INC. | $15.04 | 2019 | |
| Genentech USA, INC. | $14.93 | 2019 | |
| Glaxosmithkline, LLC. | $14.38 | 2023 | Shingrix, Bexsero |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $14.19 | 2020 | |
| Merck Sharp & Dohme LLC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.